流感疫苗接种与房颤及心血管结局的关联
基于TriNetX全球数据库的回顾性队列研究,纳入2022年有常规就诊的成人,以1:1倾向评分匹配65个基线变量后比较接种与未接种流感疫苗者。平均随访2.7年,接种与房颤发生风险显著降低相关(HR 0.80),全因死亡、心梗、心衰及心血管住院风险亦较低。结果支持接种作为房颤上游预防策略,但需随机试验验证。
要点
- 流感疫苗接种与房颤发生风险降低20%相关(HR 0.80,95%CI 0.76-0.84)。
- 接种组全因死亡、心梗、心衰和心血管住院风险均显著低于未接种组。
- 关联在年龄和基线心血管病亚组中方向一致,无显著效应修饰。
核心结论
- 在大规模回顾性真实世界队列中,流感疫苗接种与房颤发生及多种心血管结局风险降低相关。
- 研究结果支持将疫苗接种作为房颤预防的潜在上游策略,并提示需专门设计针对房颤结局的随机试验。
研究设计与样本
- 回顾性队列研究,采用真实世界目标试验模拟框架,数据来自TriNetX全球协作联邦研究网络。
- 纳入2022年有常规医疗就诊的成人,暴露定义为前一年内接种流感疫苗,对照为无接种记录者。
主要发现
- 平均随访2.7±0.7年,接种组房颤发生风险显著低于未接种组(HR 0.80,95%CI 0.76-0.84;P<.0001)。
- 房颤年化绝对发生率在接种组为0.9%,未接种组为1.1%。
- 接种组全因死亡风险较低(HR 0.85,95%CI 0.82-0.89)。
- 接种组心肌梗死风险较低(HR 0.91,95%CI 0.86-0.97)。
- 接种组新发心衰风险较低(HR 0.92,95%CI 0.88-0.96),心血管相关住院风险亦较低(HR 0.97,95%CI 0.95-0.99)。
临床怎么用
- 在临床实践中,可将流感疫苗接种视为降低房颤及心血管事件风险的潜在上游措施。
- 对高龄及已有心血管病者,接种的关联方向一致,支持在高危人群中继续推进接种。
局限性
- 为回顾性观察性研究,存在残余混杂可能,无法确立因果关系。
- 暴露依赖接种记录,可能低估或错分疫苗接种状态。
- 随访时间平均2.7年,长期关联未明确。
- 需专门针对房颤结局的随机试验验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Influenza infection triggers cardiovascular events, and vaccination confers cardiovascular benefit in high-risk populations. Its role in preventing incident atrial fibrillation (AF) and cardiovascular outcomes in clinical practice remains uncertain. These associations were evaluated using a real-world target-trial emulation framework. METHODS: A retrospective cohort study was conducted using the TriNetX Global Collaborative Federated Research Data Network including adults with a routine healthcare visit in 2022. Influenza vaccination within the preceding year defined exposure; comparators had no recorded vaccination. A 1:1 propensity score matching across 65 baseline variables was applied. Outcomes included incident AF, cardiovascular events, and mortality, with subgroup analyses by age and baseline cardiovascular disease. RESULTS: After matching, 276 888 patients (138 444 per group) were included with excellent covariate balance. During a mean follow-up of 2.7 ± 0.7 years, influenza vaccination was associated with a significantly lower risk of incident AF [hazard ratio (HR) 0.80, 95% confidence interval (CI) 0.76-0.84; P < .0001]. The absolute annualized incidence of AF was 0.9% in vaccinated patients vs 1.1% in non-vaccinated patients. Vaccinated patients also had lower risks of all-cause mortality (HR 0.85, 95% CI 0.82-0.89), myocardial infarction (HR 0.91, 95% CI 0.86-0.97), incident heart failure (HR 0.92, 95% CI 0.88-0.96), and cardiovascular-related hospitalization (HR 0.97, 95% CI 0.95-0.99). Associations were directionally consistent across age and cardiovascular disease subgroups, without significant effect modification. CONCLUSIONS: In a large retrospective observational real-world cohort, influenza vaccination was associated with lower risks of incident AF and multiple cardiovascular outcomes. These findings support vaccination as a potential upstream strategy for AF prevention and highlight the need for randomized trials specifically designed to address AF-related outcomes.
引用
- Fauchier L, Guglieri M, Lenormand T, et al. Influenza vaccination, incident atrial fibrillation, and cardiovascular outcomes. Eur Heart J. 2026. PMID: 42431720. doi:10.1093/eurheartj/ehag543
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。